Paradigm Biocapital Advisors LP 13F: Quarter-over-Quarter Portfolio Changes
Paradigm Biocapital Advisors LP reported a disclosed portfolio value of approximately $4.9 billion in its latest SEC Form 13F-HR filing for Q1 2026, up 31.0% quarter on quarter. Over the quarter, the fund initiated 10 new positions, bought more shares in 13 holdings, trimmed 7 holdings, and exited 4 positions.
Paradigm Biocapital Advisors LP's top buy was a new stake in Insmed INC (INSM) , equal to 4.2% of the disclosed portfolio. Its top sell was Cidara Therapeutics INC (CDTX) . The fund exited the position completely after it had accounted for 4.5% of the previous portfolio.
New PositionsQ1 2026
Securities disclosed for the first time in Q1 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| INSMED INC | INSM | 4.2% | History → |
| BELITE BIO INC | BLTE | 3.6% | History → |
| CENTESSA PHARMACEUTICALS PLC | CNTA | 2.9% | Holders → |
| CYTOKINETICS INC | CYTK | 2.0% | Holders → |
| TANGO THERAPEUTICS INC | TNGX | 1.7% | Holders → |
| MAZE THERAPEUTICS INC | MAZE | 1.7% | Holders → |
| TYRA BIOSCIENCES INC | TYRA | 1.6% | Holders → |
| MIRUM PHARMACEUTICALS INC | MIRM | 1.2% | Holders → |
| VERADERMICS INC | MANE | 0.7% | Holders → |
| STRUCTURE THERAPEUTICS INC | GPCR | 0.5% | Holders → |
Top BuysQ1 2026
Showing the top 10 buys among 13 existing positions where the fund bought more shares in Q1 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| TERNS PHARMACEUTICALS INC | TERN | +1.5% | +173.5% | Holders → |
| VIRIDIAN THERAPEUTICS INC | VRDN | +0.1% | +118.2% | Holders → |
| ORUKA THERAPEUTICS INC | ORKA | +0.9% | +35.7% | Holders → |
| SPYRE THERAPEUTICS INC | SYRE | +0.7% | +33.4% | Holders → |
| LEXEO THERAPEUTICS INC | LXEO | +-0.5% | +29.8% | Holders → |
| APOGEE THERAPEUTICS INC | APGE | +0.0% | +20.0% | Holders → |
| VAXCYTE INC | PCVX | +0.7% | +17.8% | History → |
| GENMAB A/S | GMAB | +-1.4% | +13.2% | History → |
| EDGEWISE THERAPEUTICS, INC. | EWTX | +0.4% | +12.6% | History → |
| OLEMA PHARMACEUTICALS INC | OLMA | +-2.6% | +6.3% | Holders → |
Top SellsQ1 2026
The fund's top sells among positions it retained in Q1 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| UROGEN PHARMA LTD | URGN | -2.2% | 61.9% | Holders → |
| BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | -0.6% | 61.6% | Holders → |
| SCHOLAR ROCK HLDG CORP | SRRK | -2.4% | 60.0% | Holders → |
| ABIVAX SA | ABVX | -3.4% | 45.5% | Holders → |
| ORIC PHARMACEUTICALS INC | ORIC | -0.1% | 29.2% | Holders → |
| ERASCA INC | ERAS | 2.0% | 26.6% | History → |
| EYEPOINT INC | EYPT | -1.0% | 14.9% | Holders → |
Full ExitsQ1 2026
Positions present in the prior 13F-HR filing that no longer appear in Q1 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| CIDARA THERAPEUTICS INC | CDTX | 4.5% |
| CRINETICS PHARMACEUTICALS IN | CRNX | 2.8% |
| BRIDGEBIO PHARMA INC | BBIO | 1.4% |
| OCULAR THERAPEUTIX INC | OCUL | 1.0% |
Net Portfolio Value ChangeQ1 2026
- $3.7BPrior quarter
- $4.9BCurrent quarter
- +$1.2BNet delta
- +31.0%% change
Methodology & FAQ
How Paradigm Biocapital Advisors LP Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Paradigm Biocapital Advisors LP: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description — including how confidential treatment filings are handled — is documented in the Methodology.
What stocks did Paradigm Biocapital Advisors LP buy in Q1 2026?
In Q1 2026, Paradigm Biocapital Advisors LP initiated 10 new positions (INSMED INC (INSM), BELITE BIO INC (BLTE), CENTESSA PHARMACEUTICALS PLC (CNTA), CYTOKINETICS INC (CYTK), TANGO THERAPEUTICS INC (TNGX), MAZE THERAPEUTICS INC (MAZE), TYRA BIOSCIENCES INC (TYRA), MIRUM PHARMACEUTICALS INC (MIRM), VERADERMICS INC (MANE), STRUCTURE THERAPEUTICS INC (GPCR)); bought more shares of TERNS PHARMACEUTICALS INC (TERN), VIRIDIAN THERAPEUTICS INC (VRDN), ORUKA THERAPEUTICS INC (ORKA), SPYRE THERAPEUTICS INC (SYRE), LEXEO THERAPEUTICS INC (LXEO) — the largest 5 of 13 adds.
What stocks did Paradigm Biocapital Advisors LP sell in Q1 2026?
In Q1 2026, Paradigm Biocapital Advisors LP fully sold 4 positions (CIDARA THERAPEUTICS INC (CDTX), CRINETICS PHARMACEUTICALS IN (CRNX), BRIDGEBIO PHARMA INC (BBIO), OCULAR THERAPEUTIX INC (OCUL)); reduced holdings in UROGEN PHARMA LTD (URGN), BRIDGEBIO ONCOLOGY THERAPEUT (BBOT), SCHOLAR ROCK HLDG CORP (SRRK), ABIVAX SA (ABVX), ORIC PHARMACEUTICALS INC (ORIC) — the largest 5 of 7 reductions.
Which positions did Paradigm Biocapital Advisors LP initiate in Q1 2026?
Paradigm Biocapital Advisors LP established 10 new positions in Q1 2026: INSMED INC (INSM, 4.2%), BELITE BIO INC (BLTE, 3.6%), CENTESSA PHARMACEUTICALS PLC (CNTA, 2.9%), CYTOKINETICS INC (CYTK, 2.0%), TANGO THERAPEUTICS INC (TNGX, 1.7%), MAZE THERAPEUTICS INC (MAZE, 1.7%), TYRA BIOSCIENCES INC (TYRA, 1.6%), MIRUM PHARMACEUTICALS INC (MIRM, 1.2%), VERADERMICS INC (MANE, 0.7%), STRUCTURE THERAPEUTICS INC (GPCR, 0.5%).
Which existing positions saw the largest allocation increases for Paradigm Biocapital Advisors LP in Q1 2026?
Of 13 existing positions with share-count increases in Q1 2026, the largest were: TERNS PHARMACEUTICALS INC (TERN, +1.5% weight, +173.5% shares), VIRIDIAN THERAPEUTICS INC (VRDN, +0.1% weight, +118.2% shares), ORUKA THERAPEUTICS INC (ORKA, +0.9% weight, +35.7% shares), SPYRE THERAPEUTICS INC (SYRE, +0.7% weight, +33.4% shares), LEXEO THERAPEUTICS INC (LXEO, +-0.5% weight, +29.8% shares), APOGEE THERAPEUTICS INC (APGE, +0.0% weight, +20.0% shares), VAXCYTE INC (PCVX, +0.7% weight, +17.8% shares), GENMAB A/S (GMAB, +-1.4% weight, +13.2% shares), EDGEWISE THERAPEUTICS, INC. (EWTX, +0.4% weight, +12.6% shares), OLEMA PHARMACEUTICALS INC (OLMA, +-2.6% weight, +6.3% shares).
Which positions did Paradigm Biocapital Advisors LP fully exit in Q1 2026?
Paradigm Biocapital Advisors LP fully exited 4 positions in Q1 2026: CIDARA THERAPEUTICS INC (CDTX, last-reported weight 4.5%), CRINETICS PHARMACEUTICALS IN (CRNX, last-reported weight 2.8%), BRIDGEBIO PHARMA INC (BBIO, last-reported weight 1.4%), OCULAR THERAPEUTIX INC (OCUL, last-reported weight 1.0%).
Which existing positions saw the largest allocation reductions for Paradigm Biocapital Advisors LP in Q1 2026?
Of 7 existing positions with share-count reductions in Q1 2026, the largest were: UROGEN PHARMA LTD (URGN, -2.2% weight, -61.9% shares), BRIDGEBIO ONCOLOGY THERAPEUT (BBOT, -0.6% weight, -61.6% shares), SCHOLAR ROCK HLDG CORP (SRRK, -2.4% weight, -60.0% shares), ABIVAX SA (ABVX, -3.4% weight, -45.5% shares), ORIC PHARMACEUTICALS INC (ORIC, -0.1% weight, -29.2% shares), ERASCA INC (ERAS, 2.0% weight, -26.6% shares), EYEPOINT INC (EYPT, -1.0% weight, -14.9% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.